Skip to main content
Equibles
INSM logo

INSM · INSMED Inc · Investor Relations

Track INSM — free

Use INSM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INSM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$121.16 +3.09 (+2.62%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Market Cap
$26.58B
Shares
219.38M
Volume · Nov 13 1.54M Avg daily vol (3M) 2.77M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-16 00:00 UTC 2026 Jefferies Global Healthcare Conference in London Conference
2026-11-16 00:00 UTC Jefferies Global Healthcare Conference Conference
2026-12-01 00:00 UTC 9th Annual Evercore Healthcare Conference Conference
2026-12-01 14:10 UTC Evercore 9th Annual Healthcare Conference Conference

Recent news

Date Headline
2026-11-04 Insmed to Present at November and December 2026 Investor Conferences
2026-10-29 Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
2026-10-20 Insmed Appoints Two New Directors to Its Board
2026-10-19 Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
2026-10-15 Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
2026-10-14 Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
2026-10-05 Insmed Announces CFO Transition
2026-08-06 Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
2026-07-16 Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
2026-05-07 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
2026-04-07 Insmed Provides Clinical Update on Phase 2b CEDAR Study
2026-03-23 Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE ® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
2026-02-19 Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-01-09 Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
2025-12-17 Insmed Provides Clinical and Business Update
2025-11-18 European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Past events

Date Event Type
2026-10-29 Q3 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-09-14 24th Annual Morgan Stanley Global Healthcare Conference Conference
2026-09-09 12th Annual Cantor Fitzgerald Global Healthcare Conference Conference
2026-08-06 Q2 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-07-16 12-Month Results from Ongoing Open-Label Extension Study of TPIP in PAH Patients Event
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-05-20 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-05-12 BofA Securities 2026 Healthcare Conference Conference
2026-05-07 Q1 Earnings conference call (announced in 8-K) Earnings call
2026-03-23 Earnings conference call (announced in 8-K) Earnings call
2026-02-19 Earnings conference call (announced in 8-K) Earnings call

Source: https://investor.insmed.com/index

Key facts CIK 1104506 CUSIP 457669307 13F (30d) 550 filings 499 filers Visit website Investor relations